

BioBusiness Asia 2009

Company Name	Novo Nordisk A/S		
Presenter	Tomas Landh	Title	Director Strategy and Sourcing
Address	Novo Nordisk Park, 2760 Måløv, Denmark		
Website	www.novonordisk.com		
No. of employee	27,000	Year of foundation	1923
Company Categories	<input type="checkbox"/> Novel Therapeutics <input type="checkbox"/> Genomics <input checked="" type="checkbox"/> Pharmaceuticals <input type="checkbox"/> R&D Service <input type="checkbox"/> Medical Devices <input type="checkbox"/> Other _____		
Paid-in Capital	-		
Company Stage	<input type="checkbox"/> Seed <input type="checkbox"/> Start up <input type="checkbox"/> Expansion <input checked="" type="checkbox"/> Mezzanine		
Company Overview	<p>Novo Nordisk is a global healthcare company and a worldwide market leader in diabetes care with a full portfolio of insulin analogs, the broadest portfolio of insulin delivery systems and a leading position in the global injection device market. Novo Nordisk also has a leading position in hemophilia with inhibitors, growth hormone disorders, and hormone replacement therapy.</p> <p>Novo Nordisk is committed to research and development of new medicines. Our current research and development pipeline is focused on proteins and peptides within:</p> <ul style="list-style-type: none"> • Diabetes • Hemophilia and hemostasis management • Chronic inflammation and autoimmune diseases. 		
Company History	<p>Novo Nordisk is a healthcare company headquartered in Denmark, a world leader in diabetes care, and hemostasis management, with the industry's widest diabetes product portfolio and the most advanced insulin delivery systems, and a leading position in growth disorders and HRT.</p> <p>Novo Nordisk's current R&D pipeline is focused on new diabetes products, new indications for our coagulant recombinant factors.</p>		
Main Products/ Service & Niche of Products/ Service	Levemir® (insulin detemir), NovoMix® (biphasic insulin aspart), NovoRapi® (insulin aspart), NovoSeven® (recombinant factor VIIa) / Protein therapeutics		
Market Potentials	See www.novonordisk.com		

<p>Company Core Competence or Competitive Advantage</p>	<p>See www.novonordisk.com</p>
<p>Partnering Objectives</p>	<p>Partnership opportunities - Novo Nordisk's interest areas:</p> <p>Diabetes:</p> <ul style="list-style-type: none"> • Insulins • GLP-1 • Therapeutic proteins and peptides for: <ul style="list-style-type: none"> - Insulin resistance/secretion - Glucose regulation via glucose dependent mechanisms - Glucose regulation and either obesity or hyperlipidemia/atherosclerosis - Beta cell regeneration, proliferation or neogenesis - Prevention and/or intervention of diabetes - Inflammation related to diabetes - Obesity. <p>Hemophilia:</p> <ul style="list-style-type: none"> • Improvement of therapies for patients with inhibitors • Improvement of replacement therapies for patients with hemophilia A or B without inhibitors • Novel non-replacement therapies that improve hemostasis. <p>Chronic inflammatory and autoimmune disorders:</p> <ul style="list-style-type: none"> • Innovative protein/antibody therapies • Targets focusing on: <ul style="list-style-type: none"> - Surface molecules on cells involved in immune regulation, particularly T cells, dendritic cells and monocytes/macrophages - Cytokines and chemokines • Companion diagnostics. <p>Protein technologies:</p> <ul style="list-style-type: none"> • Formulation • Expression and production • Engineering and modification • Manufacturing. <p>Protein delivery systems (formulations and devices):</p> <ul style="list-style-type: none"> • Injection, infusion • Sustained release • Oral, nasal, transdermal. <p>For more information please visit our website www.novonordisk.com/science/partnering</p>